
SGLT2 inhibitors transform CKD management. Affecting 14% of the U.S. population, chronic kidney disease (CKD) carries a high risk of progression, cardiovascular events, and mortality. The EMPA-KIDNEY trial (2023) demonstrated the efficacy of empagliflozin, marking a breakthrough after decades of stagnation. Herrington et al. now report long-term follow-up results, further solidifying the role of SGLT2 inhibitors in improving outcomes for CKD patients.
Like
Save
Share